Nutraceutical composition (yeast ß-glucan, prebiotics, minerals, and silymarin) predicts improvement of sleep quality and metabolic parameters: A randomized pilot study.

BACKGROUND & AIMS: The search for integrative and natural therapies that favor homeostasis to boost sleep and diet quality took place for young adult populations as a non-pharmacological strategy for long-term good quality of life. Thus, the present pilot study aims to investigate the effects of 90-day consumption of a nutraceutical composition on the neuro-immune-endocrine axis, providing better sleep quality and health improvement. METHODS: For this, from March 2021 to June 2021, twenty-two Brazilian young adult volunteers (women and men) with BMI between 18.5 and 34.9 kg/m2 were divided into three distinct supplementation groups: NSupple; NSupple plus_S, and NSupple plus. Briefly, the supplement compositions included yeast ß-glucan, prebiotics, and minerals in different concentrations associated or not with the herbal medicine silymarin. Neither nutritional nor physical activity interventions were performed during this pilot study period. The anthropometrics measures, questionnaires answer data, and harvest blood for metabolic, inflammatory, and hormonal tests were collected at baseline time (day zero-T0) and day 90 (T90) post-supplementation. RESULTS: Our results highlight that the supplementation reduced body mass index (BMI), Waist-to-height ratio (WHtR), waist circumference, AST/ALT ratio, alkaline phosphatase, and HbA1c. Post-supplementation the IL-6 and IL-10 levels and the sleep, humor, and quality of life scores were suggested to improve. Sleep quality improvement seems to predict the reduction of adiposity-related body measures. CONCLUSION: In sum, the nutraceutical supplementation might be related to anthropometric, metabolic, and endocrine parameters after 90 days reflecting on perception of humor, sleep, and life quality enhancement. However, it is important to recognize the limitation of the data presented considering that this was a pilot study. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, identifier NCT04810572 registered on 20th February 2021.

Hepatitis autoinmune, revisión a propósito de un caso / Autoimmune hepatitis, review in relation to a case

El presente es un caso de hepatitis autoinmune (HAI) con datos de citolisis importante (AST y ALT elevadas) e insuficiencia hepática (tiempo de protrombina prolongado y colinesterasa baja). El proceso que lleva al diagnóstico de esta entidad clínica es mostrado de manera detallada y evidente, resaltando las claves diagnósticas como la hipergammaglobulinemia. La clasificación del caso como hepatitis autoinmune del tipo I, sostenido en marcadores seroinmunológicos, como los anticuerpos antinucleares (ANA), antimúsculo liso (SMA), antiactina, en el presente caso estuvieron positivos, la ausencia de infección de virus hepatotropos y las condiciones epidemiológicas que dan luces al diagnóstico de HAI. Se instaura tratamiento inmunosupresor con prednisona y azatioprina y la remisión clínica y de laboratorio son evidentes. Se revisa factores pronósticos los cuales se asocia con los niveles y gravedad de las alteraciones de laboratorio, a las cuales se les da un peso importante al momento de indicar los inmunosupresores. Todos estos aspectos sostenidos por la más diversa evidencia.

This is a case of autoimmune hepatitis (AIH) with important cytolysis data (high AST and ALT) and liver insufficiency (prolonged prothrombin time an low cholinesterase). The process that leads to this diagnosis is showed in a detailed an obvious way, standing out the diagnosis keys such as hypergammaglobulinemia. Classification of the case as autoimmune hepatitis type I, sutained by seroimmunological markers such as antinuclear antibodies (ANA), anti smooth muscle (SMA), antiactina, in this case wer positive, the absence of infection by hepatotropic viruses and epidemiological conditions lighten the diagnosis of AIH. An immunosuppressive treatment is established with prednisone and azathioprine and clinical and laboratory remissions are evident. Prognosis factors are checked and are associated with levels and seriousness of laboratory alterations, which have importance at the time of prescribing the immunosupressives. All these aspects sustained by the most varied evidence.